Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2015 Oct 13

PMID 26457112

Citations 26

Authors

Tina Blazevic

Elke H Heiss

Atanas G Atanasov

Johannes M Breuss

Verena M Dirsch

Pavel Uhrin

Affiliations

Soon will be listed here.

Abstract

Indirubin is the active component of Danggui Longhui Wan, a traditional Chinese medicine formulation. The encouraging clinical results from the 1980s obtained in chronic myelocytic leukemia patients treated with indirubin stimulated numerous studies on this compound. These investigations explored the use of indirubin in different types of cancer and reported the synthesis of novel derivatives with improved chemical and pharmacokinetic properties. In this paper, we review the impressive progress that has been made in elucidating the mechanistic understanding of how indirubin and its derivatives affect physiological and pathophysiological processes, mainly by inhibition of cell proliferation and induction of cell death. Furthermore, we survey the therapeutic use of these compounds in combating proliferative diseases such as cancer, restenosis, and psoriasis.

Citing Articles

New imidazolidindionedioximes and their Pt(II) complexes: synthesis and investigation of their antitumoral activities on breast cancer cells.

Karahan E, Gencoglu Katmerlikaya T, Onal E, Dag A, Gurek A, Ahsen V Turk J Chem. 2024; 48(4):582-596.

PMID: 39296792 PMC: 11407372. DOI: 10.55730/1300-0527.3681.

Podophyllotoxin: Recent Advances in the Development of Hybridization Strategies to Enhance Its Antitumoral Profile.

Miranda-Vera C, Hernandez A, Garcia-Garcia P, Diez D, Garcia P, Castro M Pharmaceutics. 2023; 15(12).

PMID: 38140069 PMC: 10747284. DOI: 10.3390/pharmaceutics15122728.

Vincamine, from an antioxidant and a cerebral vasodilator to its anticancer potential.

Ren Y, DeRose K, Li L, Gallucci J, Yu J, Kinghorn A Bioorg Med Chem. 2023; 92:117439.

PMID: 37579526 PMC: 10530545. DOI: 10.1016/j.bmc.2023.117439.

PPRX-1701, a nanoparticle formulation of 6'-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models.

Zdioruk M, Jimenez-Macias J, Nowicki M, Manz K, Pennell K, Koch M Cell Rep Med. 2023; 4(5):101019.

PMID: 37060903 PMC: 10213750. DOI: 10.1016/j.xcrm.2023.101019.

New insights into the characteristics of DRAK2 and its role in apoptosis: From molecular mechanisms to clinically applied potential.

Zheng Y, Li X, Kuang L, Wang Y Front Pharmacol. 2022; 13:1014508.

PMID: 36386181 PMC: 9649744. DOI: 10.3389/fphar.2022.1014508.

References

Li Y, Ligr M, McCarron J, Daniels G, Zhang D, Zhao X . Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion. Clin Cancer Res. 2011; 17(13):4414-24. PMC: 3196615. DOI: 10.1158/1078-0432.CCR-11-0431. View

Wee X, Yang T, Go M . Exploring the anticancer activity of functionalized isoindigos: synthesis, drug-like potential, mode of action and effect on tumor-induced xenografts. ChemMedChem. 2012; 7(5):777-91. DOI: 10.1002/cmdc.201200018. View

Hoessel R, Leclerc S, Endicott J, Nobel M, Lawrie A, Tunnah P . Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999; 1(1):60-7. DOI: 10.1038/9035. View

Nam S, Wen W, Schroeder A, Herrmann A, Yu H, Cheng X . Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol. 2012; 7(3):369-78. PMC: 3968804. DOI: 10.1016/j.molonc.2012.10.013. View

Braig S, Kressirer C, Liebl J, Bischoff F, Zahler S, Meijer L . Indirubin derivative 6BIO suppresses metastasis. Cancer Res. 2013; 73(19):6004-12. DOI: 10.1158/0008-5472.CAN-12-4358. View

Zhen Y, Sorensen V, Jin Y, Suo Z, Wiedlocha A . Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK. Oncogene. 2007; 26(44):6372-85. DOI: 10.1038/sj.onc.1210473. View

Meijer L, Skaltsounis A, Magiatis P, Polychronopoulos P, Knockaert M, Leost M . GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol. 2004; 10(12):1255-66. DOI: 10.1016/j.chembiol.2003.11.010. View

Hoffmann R, Mintz G . Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J. 2000; 21(21):1739-49. DOI: 10.1053/euhj.2000.2153. View

Tran T, Sneed B, Haider J, Blavo D, White A, Aiyejorun T . Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res. 2007; 67(23):11386-92. DOI: 10.1158/0008-5472.CAN-07-3126. View

10.

Yoon J, Kim S, Kwon S, Park J, Park H, Kim Y . 5'-Nitro-indirubinoxime induces G1 cell cycle arrest and apoptosis in salivary gland adenocarcinoma cells through the inhibition of Notch-1 signaling. Biochim Biophys Acta. 2009; 1800(3):352-8. DOI: 10.1016/j.bbagen.2009.11.007. View

11.

Magiatis P, Pappas P, Gaitanis G, Mexia N, Melliou E, Galanou M . Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin. J Invest Dermatol. 2013; 133(8):2023-30. PMC: 3714356. DOI: 10.1038/jid.2013.92. View

12.

Zhang X, Song Y, Wu Y, Dong Y, Lai L, Zhang J . Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer. 2011; 129(10):2502-11. DOI: 10.1002/ijc.25909. View

13.

Gu Y, Li G, Yang Y, Fu J, Li C . [Synthesis of some halogenated indirubin derivatives]. Yao Xue Xue Bao. 1989; 24(8):629-32. View

14.

Chen F, Li L, Ma D, Yan S, Sun J, Zhang M . Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment. Leuk Res. 2009; 34(2):e75-7. DOI: 10.1016/j.leukres.2009.09.001. View

15.

Polychronopoulos P, Magiatis P, Skaltsounis A, Myrianthopoulos V, Mikros E, Tarricone A . Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004; 47(4):935-46. DOI: 10.1021/jm031016d. View

16.

Cockle J, Picton S, Levesley J, Ilett E, Carcaboso A, Short S . Cell migration in paediatric glioma; characterisation and potential therapeutic targeting. Br J Cancer. 2015; 112(4):693-703. PMC: 4333505. DOI: 10.1038/bjc.2015.16. View

17.

Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, Magiatis P, Ferandin Y, Durieu E . Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. ACS Med Chem Lett. 2013; 4(1):22-26. PMC: 3545483. DOI: 10.1021/ml300207a. View

18.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

19.

Ji X, Liu X, Li K, Chen R, Wang L . Pharmacological studies of meisoindigo: absorption and mechanism of action. Biomed Environ Sci. 1991; 4(3):332-7. View

20.

Lee M, Liu Y, Chen M, Wu J, Ho H, Wang Q . Indirubin-3'-monoxime promotes autophagic and apoptotic death in JM1 human acute lymphoblastic leukemia cells and K562 human chronic myelogenous leukemia cells. Oncol Rep. 2013; 29(5):2072-8. DOI: 10.3892/or.2013.2334. View